Pulse.

a daily field guide to health research that matters

◆ Console

‹ Wed · 11 Nov 2026
Standard addition

Orelabrutinib plus R-CHOP in patients with newly diagnosed non-GCB double-expressor DLBCL: A single-arm, phase II study.

A new drug combination achieves nearly 90% complete remission in high-risk lymphoma, though managing side effects remains important.

The study evaluated first-line orelabrutinib plus R-CHOP in high-risk diffuse large B-cell lymphoma. The regimen produced an 89.8% complete response rate and an estimated two-year progression-free survival rate of 82.0%, with grade 3 or higher adverse events in 51.0% of patients.

What the study was

Study design
Multicenter single-arm phase II clinical trial
Population
49 patients with newly diagnosed non-GCB double-expressor diffuse large B-cell lymphoma
Sample size
49
Category
Treatment Innovation
Maturity
Exploratory
Journal
British journal of haematology

Why it surfaced

A prospective phase II study reports encouraging response and survival data, but the single-arm design and small cohort require confirmation

A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.